ArticleCancer cell international2026
Neuregulin induces prostate cancer cell migration via HER3/HER2-FAK/Src signaling axis.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuregulin-1 β (NRG1) has emerged as a potential regulator of cancer cell migration, but its role in prostate cancer progression remains poorly understood. This study investigated the effects of NRG1 on prostate cancer cell behavior and elucidated the underlying molecular mechanisms. We examined NRG1 effects on cell migration and proliferation in three prostate cancer cell lines (PC-3, DU145, and LNCaP) using transwell migration assays. Protein-protein interactions were investigated using co-immunoprecipitation. Loss-of-function studies employed siRNA-mediated knockdown of key signaling components. Epithelial-mesenchymal transition (EMT) markers were assessed by Western blot analysis. Among the three cell lines tested, only DU145 cells showed enhanced migration in response to NRG1 treatment, which correlated with robust HER family receptor expression and functional HER3 phosphorylation. Specifically, HER3 knockdown completely abolished NRG1-induced migration and downstream signaling. Co-immunoprecipitation revealed that NRG1 specifically promotes HER3/HER2 heterodimerization and facilitates formation of a Src-centered signaling complex including FAK. Both FAK and Src were essential for NRG1-induced migration, as demonstrated by siRNA knockdown experiments. NRG1 treatment induced epithelial-mesenchymal transition characterized by dramatic Snail upregulation. This upregulation was dependent on the FAK/Src axis and GSK3β phosphorylation. NRG1 selectively promotes prostate cancer cell migration through a signaling cascade involving HER3/HER2 heterodimerization, FAK/Src activation, GSK3β phosphorylation, and Snail-mediated EMT. The cell line-specific response pattern suggests that neuregulin signaling may be relevant in specific prostate cancer subtypes characterized by particular receptor expression profiles. These findings provide mechanistic insight into NRG1-induced cell migration, reveal a partial EMT phenotype relevant to metastasis, and identify multiple potential therapeutic targets (HER3, FAK, Src, GSK3β) for inhibiting prostate cancer progression, particularly in castration-resistant prostate cancer subtypes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.